HAWTHORNE, N.Y.--(BUSINESS WIRE)--Nov. 10, 2005--Acorda Therapeutics announced today that it has entered into an agreement with the Contract Sales and Services business of Cardinal Health (NYSE: CAH) Pharmaceutical Technologies and Services segment to expand the sales force for Acorda’s Zanaflex Capsules(TM) (tizanidine hydrochloride) with approximately 160 contract sales representatives to address the primary care market.
